606 results on '"van Veldhuisen, D J"'
Search Results
152. To bind or not to bind: potassium-lowering drugs in heart failure
153. [Research set-up concerning the effectiveness of heart failure clinics in the Netherlands]
154. Efficacy and safety of ibopamine in congestive heart failure
155. Heart rates in cardiac resynchronization: the art of optimal device programming
156. -blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure
157. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation
158. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate
159. Compliance with non-pharmacological recommendations and outcome in heart failure patients
160. Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [Eur Heart J 2008;29:2388-2442]
161. Telomere length and psychological well-being in patients with chronic heart failure
162. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population
163. Anaemia and renal dysfunction in chronic heart failure
164. Poster Session 4: CRT I
165. Poster Session 4: CRT II
166. Poster Session 1: Ablation of SVT and VT
167. Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up
168. Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing
169. Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure
170. Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy
171. Erythropoietin, haemoglobin, heart failure, and mortality: reply
172. Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time
173. Psychology and cardiology: do not forget the heart failure patient
174. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regiments of darbepoetin alfa in patients with heart failure and anaemia: reply
175. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
176. New dopamine agonists in cardiovascular therapy
177. Clinical and prognostic value of advanced glycation end-products in chronic heart failure
178. Management of atrial fibrillation in patients with heart failure
179. Angiotensin II Type 2 Receptor Vasoactivity in Internal Mammary Arteries of Patients With Coronary Artery Disease
180. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
181. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP: reply
182. Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment
183. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well
184. Heart failure, atrial fibrillation, and beta-blockers
185. Leitliniengerechte Herzinsuffizienzbehandlung in Deutschland
186. Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
187. Circulating apoptosis-related proteins in long-term disease free breast cancer survivors
188. BackMatter.
189. FrontMatter.
190. IMPAIRED MODULATION OF ARTERIAL BAROREFLEX CONTROL OF BLOOD PRESSURE. HEART RATE AND PERIPHERAL RESISTANCE DURING LOWER BODY NEGATIVE PRESSURE IN CHRONIC HEART FAILURE
191. Physiological parameters during the initial stages of cardiopulmonary exercise testing in patients with chronic heart failure: Their value in the assessment of clinical severity and prognosis
192. Management of atrial fibrillation in the setting of heart failure
193. Treatment of mild heart failure: the place of diuretics and ibopamine
194. Hemodynamic and Autonomic Effects of Intravenous Saterinone in Patients with Chronic Heart Failure
195. Right-heart dysfunction in women with congenital heart disease and pre-eclampsia.
196. Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery
197. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure
198. Relation between myocardial -adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril
199. Exploratory Study of the Effects of Single Doses of Isomazole on Hemodynamics and Heart Rate Variability Parameters in Chronic Heart Failure
200. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.